Clinician's Guide for Pediatric Anti-obesity Medications

Wesley P Dutton; Nina Paddu; Amy Braddock; Brooke Sweeney

doi:10.1016/j.pcl.2024.07.006

Clinician's Guide for Pediatric Anti-obesity Medications

Pediatr Clin North Am. 2024 Oct;71(5):957-980. doi: 10.1016/j.pcl.2024.07.006.

Authors

Wesley P Dutton¹, Nina Paddu², Amy Braddock³, Brooke Sweeney⁴

Affiliations

¹ Harvard Medical School, Massachusetts General Hospital, Weight Center at Massachusetts General Hospital, Boston, MA, USA.
² Vanderbilt University Medical Center, Nashville, TN, USA.
³ Family and Community Medicine, University of Missouri, Columbia, MO, USA.
⁴ University of Missouri Kansas City, Children's Mercy Kansas City, Center for Children's Healthy Lifestyles & Nutrition, Kansas City, MO, USA. Electronic address: brsweeney@cmh.edu.

PMID: 39343504
DOI: 10.1016/j.pcl.2024.07.006

Abstract

The recent advent of highly effective anti-obesity medications (AOM) provides pediatric clinicians a powerful tool to augment the treatment of obesity and improve outcomes. The 2023 American Academy of Pediatrics guidelines state clinicians "should offer adolescents 12 years and older with obesity weight loss pharmacotherapy, according to medication indications, risks, and benefits, as an adjunct to health behavior and lifestyle treatment". This article will provide an update on the integration of AOM into practice, emphasizing clinical pearls and practical tips.

Keywords: Anti-obesity medications; Pediatric obesity; Pharmacotherapy; Treatment.

Publication types

Review

MeSH terms

Adolescent
Anti-Obesity Agents* / therapeutic use
Child
Humans
Pediatric Obesity* / drug therapy
Practice Guidelines as Topic
Weight Loss / drug effects

Substances

Anti-Obesity Agents